Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

4 results found
There are 4 active filters
Clear all filters
Intellectual property and trade
maraviroc
nelfinavir

4 results found

Feature story |

28 February 2008

Patents Back on the Agenda in India

Tags HIV/AIDSIntellectual property and trade antiretroviral medicinesmaravirocvalganciclovir Roche India

Letter |

11 November 2005

Letter to Roche. Access to Viracept in China

Tags HIV/AIDSIntellectual property and trade antiretroviral medicinesnelfinavir Roche China

Press release |

13 February 2003

Bowing to pressure, Roche cuts its price for AIDS drug nelfinavir

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicinesnelfinavir Roche

Press release |

15 November 2002

AIDS Patients in Developing Countries Pay Higher Prices for Roche's Drugs Than People in Switzerland

Tags HIV/AIDSIntellectual property and trade HIV/AIDS antiretroviral medicinesnelfinavir Roche